Anacor Pharmaceuticals, Inc. (ANAC)

[surf1944]

4:03PM Anacor Pharma beats by $0.09, beats on revs (ANAC) 3.70 -0.01 : Reports Q4 (Dec) loss of $0.36 per share, $0.09 better than the Capital IQ Consensus Estimate of ($0.45); revenues rose 26.6% year/year to $3.28 mln vs the $2.63 mln consensus.

"With the positive data from both Phase 3 trials of tavaborole for the treatment of onychomycosis, we anticipate filing an NDA around the middle of this year, and we will continue to evaluate commercialization options to maximize the value of tavaborole"
"We believe our cash, cash equivalents and short-term investments will be sufficient to meet our anticipated operating requirements until we file our NDA for tavaborole in onychomycosis, which we expect to occur in mid-2013.